Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus

Abstract

Infliximab offers a therapeutic option as rescue therapy in about a quarter of patients with active UC after failing to respond to tacrolimus. This benefit has to be weighed against the risks of infectious complications.